



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



IL-9 Recombinant Monoclonal Antibody [BLR331M]

Rabbit Recombinant Monoclonal

Purified	RefSeq ID	NP_000581.1
Catalog No. A700-331CF	Uniprot ID	P15248
Lot No. 1	GeneID	3578

APPLICATIONS	WB, ICC
SPECIES REACTIVITY	Human
AMOUNT	100 µl
CONCENTRATION	1000 µg/ml
STORAGE/SHELF LIFE	2 – 8°C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Phosphate Buffered Saline (PBS) with 0.09% Sodium Azide, BSA-Free
ISOTYPE	IgG
CLONE #	BLR331M
ORIGIN	USA
PRODUCTION PROCEDURES	Recombinant antibody was purified from cell culture supernatant. Immunogen was a recombinant protein representing human Interleukin 9 (residues 19–144, NP_000581.1).

APPLICATION NOTES All western blot analysis is performed using 5% Milk-TBST for blocking and as antibody diluent. Primary antibody is incubated overnight.

Western blots of cell lysates are performed using Goat anti-Rabbit IgG Heavy and Light Chain Antibody (A120-101P).

A700-331CF is the carrier-free formulation of A700-331. This product is optimized for conjugation with enzymes, fluorochromes, biotin, radioisotopes, oligonucleotides, microspheres, and other reagents. The optimal experimental concentration of the antibody post-conjugation must be determined by the investigator.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.
Michael Spencer, PhD Date: August 5, 2024